BIOGEN INC.
Close on Oct 19, 2026
- Market cap
- $34.72B
- P/E (TTM)
- 41.3
- Dividend yield
- –
About Biogen
Biological Products, (No Diagnostic Substances), SIC 2836
Biogen is a biopharmaceutical enterprise that discovers, develops, and delivers therapies for individuals living with serious neurological conditions, rare disorders, and specialized immunological diseases. Its primary product lines encompass commercial treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, and amyotrophic lateral sclerosis, alongside collaborative therapies targeting Alzheimer's disease and postpartum depression. The company also commercializes advanced biosimilars for inflammatory diseases and holds business and financial rights to anti-CD20 oncological and immunological regimens. The business primarily serves patients affected by these complex conditions, facilitating product procurement, insurance navigation, and co-pay assistance.
The company operates globally, promoting and marketing its therapeutic portfolio across North America, Europe, Asia, Latin America, and the Middle East, with product approvals spanning the United States, Japan, China, and various European nations. Its corporate headquarters is located in Cambridge, Massachusetts, where it integrates its executive operations with research and development facilities.
Summary of the business section of Biogen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOGEN INC.
- Founded
- 1978
- Headquarters
- Cambridge, MA
- Address
- 225 Binney Street 02142
- Phone
- (617) 679-2000
- Website
- www.biogen.com
- Employees
- 7,500, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- BIIB
- Exchange
- Nasdaq
- IPO date
- Jun 10, 1996
- Shares outstanding
- 148M, Jul 27, 2026
- Public float
- $18.38B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-1, Jan 18, 2001; 2-for-1, Dec 21, 1999
- SEC CIK
- 875045
- CUSIP
- 09062X103
- ISIN
- US09062X1037
- LEI
- W8J5WZB5IY3K0NDQT671
- EIN
- 33-0112644
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher Viehbacher | President and CEO, Director | 21,095 |
| Michael Parini | Chief Legal Officer | – |
| Adam Keeney | Head of Corporate Development | 6,365 |
| Sean Godbout | Chief Accounting Officer | 1,396 |
| Robin Kramer | Chief Financial Officer | 9,024 |
| Susan H. Alexander | EVP Chief Legal Officer | 58,537 |
| Ginger Gregory | EVP, Human Resources | 22,359 |
| Priya Singhal | Head of Development | 8,043 |
| Rachid Izzar | Head of Global Product Strat. | 11,786 |
| Nicole Murphy | Head of Pharm Ops and Tech | 19,611 |
| Jane Grogan | Head of Research | 3,176 |
| Michael R. McDonnell | EVP, Chief Financial Officer | 24,341 |
| Lloyd Minor | Director | 2,689 |
| Monish D. Patolawala | Director | 5,215 |
| Jesus B. Mantas | Director | 11,263 |
| Stephen A. Sherwin | Director | 15,193 |
| William A. Hawkins | Director | 10,365 |
| Menelas N. Pangalos | Director | 3,875 |
| Eric K. Rowinsky | Director | 25,844 |
| Maria C. Freire | Director | 8,820 |
| Susan Langer | Director | 6,634 |
| Caroline Dorsa | Director | 31,002 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.viehbacher | $23.65M | $27.66M | $5.87M | $72 | $120 |
| FY2024 Mr.viehbacher | $24.17M | $1.25M | $6.37M | $62 | $91 |
| FY2023 Mr.viehbacher | $4.07M | -$4.50M | $6.26M | $106 | $92 |
| FY2023 Mr.vounatsos | $0 | $0 | $6.26M | $106 | $92 |
| FY2022 Mr.viehbacher | $30.49M | $27.55M | $5.88M | $113 | $89 |
| FY2022 Mr.vounatsos | $26.63M | $5.90M | $5.88M | $113 | $89 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 7,500 employees worldwide.”
Corporate history
Events identified from SEC filings